Abstract
Over 80% of patients with pancreatic carcinoma are ineligible for surgical resection at initial diagnosis. At our centre, 30 such patients who received palliative surgery alone survived for a mean of 3.3 months. We therefore treated 34 patients with unresectable pancreatic carcinoma with additional locoregional immunotherapy via transplenic and transtumoural infusion of Interleukin 2 and Interferon-y combined with locoregional transtumoural chemotherapy. In early 1995, 17 patients (50%) had achieved a CR or PR, including 7 patients who became eligible for tumour resection following treatment. Overall, patients survived for a mean of 11 months (range 3 to 21 + months) with good quality of life. Updated results on this promising therapeutic approach will be presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
